FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304891591> ?p ?o ?g. }

• W4304891591 endingPage "209" @default.
• W4304891591 startingPage "200" @default.
• W4304891591 abstract "Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). BRCA reversion mutations are a known mechanism of acquired resistance to PARP inhibitors in multiple cancer types, although their impact and prevalence in mCRPC remain unknown.To examine the prevalence of BRCA reversion mutations in the plasma of patients with BRCA+ mCRPC after progression on rucaparib.Men with BRCA+ mCRPC enrolled in Trial of Rucaparib in Prostate Indications 2 (TRITON2) were treated with rucaparib after progressing on one to two lines of androgen receptor-directed and one taxane-based therapy. Cell-free DNA from the plasma of 100 patients, collected at the end of treatment after confirmed progression before May 5, 2020, was queried for BRCA reversion mutations using next-generation sequencing (NGS).The association of clinical efficacy and postprogression genomics was measured in 100 patients with BRCA+ mCRPC treated with rucaparib.No baseline BRCA reversion mutations were observed in 100 BRCA+ patients. NGS identified somatic BRCA reversion mutations in 39% (39/100) of patients after progression. Reversion rates were similar for BRCA2 and BRCA1, irrespective of germline or somatic status, but higher in samples with a high tumor DNA fraction. Most patients with reversions (74%, 29/39) had two or more reversion mutations occurring subclonally at lower allele frequencies than the original BRCA mutations. The incidence of BRCA reversion mutations increased with the duration of rucaparib treatment. The frequency of reversion mutations was higher in patients with an objective (58%) or a prostate-specific antigen (69%) response compared with those without either (39% and 29%, respectively).These findings suggest that BRCA reversion mutations are a significant mechanism of acquired resistance to rucaparib in patients with BRCA+ mCRPC, with evidence of subclonal convergence promoting systemic resistance.Men with BRCA mutated metastatic castration-resistant prostate cancer enrolled in TRITON2 were treated with rucaparib after progressing on one to two lines of androgen receptor-directed and one taxane-based therapy. Cell-free DNA from the plasma of 100 patients, collected after radiographic or prostate-specific antigen progression before May 5, 2020, was analyzed by next-generation sequencing and queried for BRCA reversion mutations." @default.
• W4304891591 created "2022-10-13" @default.
• W4304891591 creator A5008446157 @default.
• W4304891591 creator A5024145910 @default.
• W4304891591 creator A5024147987 @default.
• W4304891591 creator A5024309839 @default.
• W4304891591 creator A5030233600 @default.
• W4304891591 creator A5036917649 @default.
• W4304891591 creator A5040200708 @default.
• W4304891591 creator A5045415451 @default.
• W4304891591 creator A5056852049 @default.
• W4304891591 creator A5059219836 @default.
• W4304891591 creator A5062426672 @default.
• W4304891591 creator A5066372195 @default.
• W4304891591 creator A5067818010 @default.
• W4304891591 creator A5068014441 @default.
• W4304891591 creator A5071843782 @default.
• W4304891591 creator A5076200732 @default.
• W4304891591 creator A5078054913 @default.
• W4304891591 creator A5083315480 @default.
• W4304891591 creator A5086640363 @default.
• W4304891591 creator A5088951258 @default.
• W4304891591 creator A5089256383 @default.
• W4304891591 date "2023-03-01" @default.
• W4304891591 modified "2023-10-13" @default.
• W4304891591 title "Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib" @default.
• W4304891591 cites W1864344361 @default.
• W4304891591 cites W2019607817 @default.
• W4304891591 cites W2065849886 @default.
• W4304891591 cites W2106157865 @default.
• W4304891591 cites W2123696077 @default.
• W4304891591 cites W2278392405 @default.
• W4304891591 cites W2343436177 @default.
• W4304891591 cites W2462985846 @default.
• W4304891591 cites W2473878031 @default.
• W4304891591 cites W2585621330 @default.
• W4304891591 cites W2593868561 @default.
• W4304891591 cites W2607665721 @default.
• W4304891591 cites W2608211931 @default.
• W4304891591 cites W2620706965 @default.
• W4304891591 cites W2623263876 @default.
• W4304891591 cites W2741214285 @default.
• W4304891591 cites W2767593721 @default.
• W4304891591 cites W2786409274 @default.
• W4304891591 cites W2786866438 @default.
• W4304891591 cites W2800224623 @default.
• W4304891591 cites W2898861270 @default.
• W4304891591 cites W2901506506 @default.
• W4304891591 cites W2944320012 @default.
• W4304891591 cites W2947937516 @default.
• W4304891591 cites W2953100444 @default.
• W4304891591 cites W2955694621 @default.
• W4304891591 cites W3006950991 @default.
• W4304891591 cites W3011187950 @default.
• W4304891591 cites W3022760600 @default.
• W4304891591 cites W3036860998 @default.
• W4304891591 cites W3044298882 @default.
• W4304891591 cites W3049351332 @default.
• W4304891591 cites W3093351227 @default.
• W4304891591 cites W3120833111 @default.
• W4304891591 cites W3127113113 @default.
• W4304891591 cites W3133009633 @default.
• W4304891591 doi "https://doi.org/10.1016/j.eururo.2022.09.010" @default.
• W4304891591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36243543" @default.
• W4304891591 hasPublicationYear "2023" @default.
• W4304891591 type Work @default.
• W4304891591 citedByCount "9" @default.
• W4304891591 countsByYear W43048915912023 @default.
• W4304891591 crossrefType "journal-article" @default.
• W4304891591 hasAuthorship W4304891591A5008446157 @default.
• W4304891591 hasAuthorship W4304891591A5024145910 @default.
• W4304891591 hasAuthorship W4304891591A5024147987 @default.
• W4304891591 hasAuthorship W4304891591A5024309839 @default.
• W4304891591 hasAuthorship W4304891591A5030233600 @default.
• W4304891591 hasAuthorship W4304891591A5036917649 @default.
• W4304891591 hasAuthorship W4304891591A5040200708 @default.
• W4304891591 hasAuthorship W4304891591A5045415451 @default.
• W4304891591 hasAuthorship W4304891591A5056852049 @default.
• W4304891591 hasAuthorship W4304891591A5059219836 @default.
• W4304891591 hasAuthorship W4304891591A5062426672 @default.
• W4304891591 hasAuthorship W4304891591A5066372195 @default.
• W4304891591 hasAuthorship W4304891591A5067818010 @default.
• W4304891591 hasAuthorship W4304891591A5068014441 @default.
• W4304891591 hasAuthorship W4304891591A5071843782 @default.
• W4304891591 hasAuthorship W4304891591A5076200732 @default.
• W4304891591 hasAuthorship W4304891591A5078054913 @default.
• W4304891591 hasAuthorship W4304891591A5083315480 @default.
• W4304891591 hasAuthorship W4304891591A5086640363 @default.
• W4304891591 hasAuthorship W4304891591A5088951258 @default.
• W4304891591 hasAuthorship W4304891591A5089256383 @default.
• W4304891591 hasBestOaLocation W43048915911 @default.
• W4304891591 hasConcept C104317684 @default.
• W4304891591 hasConcept C109825262 @default.
• W4304891591 hasConcept C121608353 @default.
• W4304891591 hasConcept C126322002 @default.
• W4304891591 hasConcept C127716648 @default.
• W4304891591 hasConcept C143998085 @default.
• W4304891591 hasConcept C182979987 @default.

• next